Sermorelin — Research Reference

Sermorelin (also referred to as GHRH 1-29) is a synthetic analogue comprising the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor (GHRHR) on pituitary somatotroph cells and stimulates the synthesis and pulsatile release of growth hormone. Sermorelin was historically approved by the FDA for the diagnosis and treatment of idiopathic growth hormone deficiency in children, making it one of the few peptides in the GH secretagogue category with a formal regulatory history.

Quick Reference

Overview

Sermorelin was developed as a truncated synthetic analogue of the 44-amino-acid endogenous GHRH. The first 29 amino acids of GHRH retain full biological activity at the GHRH receptor — the remaining residues contribute to metabolic stability in the endogenous hormone but are not required for receptor binding and activation. Sermorelin binds GHRHR and activates adenylyl cyclase via Gαs coupling, increasing intracellular cAMP and driving GH synthesis and secretion from anterior pituitary somatotrophs.

Sermorelin was commercially available as Geref (Serono) and later as Geref Diagnostic for paediatric growth hormone deficiency testing and treatment. The commercial product was withdrawn from the US market in 2008 following the introduction of more convenient synthetic GH products, but compounding pharmacies have continued to supply sermorelin as a research compound in the United States and other markets.

Unlike exogenous synthetic growth hormone, sermorelin stimulates the pituitary to produce GH through physiological mechanisms. The resulting GH release is pulsatile and subject to normal feedback regulation — including attenuation by somatostatin and IGF-1 — which preserves the natural pulsatile pattern of GH secretion.

Reported Protocols

Standard Research Protocol

Sermorelin’s short half-life of approximately 10–20 minutes means that its window of activity at the GHRH receptor is brief. The most commonly reported approach in research accounts is administration immediately before sleep onset.

Commonly reported doses range from 200 mcg to 500 mcg per injection. The most frequently cited approach:

• Nightly administration: A single injection of 200–300 mcg subcutaneously, 30–60 minutes before sleep, on an empty stomach. This timing is intended to coincide with the early nocturnal GH pulse and to minimise somatostatin interference.
• Cycle duration: Commonly reported cycles range from 3 to 6 months. Some accounts describe longer-term use.
• Fasted state: Administration in a fasted or low-insulin state is commonly reported, as elevated insulin may blunt the GH response to GHRH stimulation.

Multiple Daily Injections

Some research accounts describe 2–3 daily injections at lower doses (100–200 mcg per injection), though the nightly single-injection protocol is more commonly cited. Injections outside the pre-sleep window are typically described as pre-workout or on waking.

Combination With GHRPs

Sermorelin is commonly reported in combination with growth hormone releasing peptides (GHRPs) such as Ipamorelin or GHRP-2. Because sermorelin and GHRPs act through distinct and complementary receptor pathways — the GHRH receptor and the ghrelin receptor (GHS-R1a) respectively — their co-administration produces a synergistic GH pulse greater than either compound alone.

The combination of sermorelin with a GHRP is among the most frequently described GH axis stacking approaches in the research literature. The two injections are commonly administered simultaneously or within a brief window of each other.

Reported Effects

Growth Hormone Elevation

Research has investigated sermorelin for its potential role in stimulating GH secretion in healthy adults and in GH-deficient populations. Studies in older adults have demonstrated measurable increases in serum GH and downstream IGF-1 levels following sermorelin administration. The physiological, pulsatile character of the GH response is considered a distinguishing feature relative to exogenous GH administration.

Body Composition

Research has investigated sermorelin for its potential role in body composition, including lean mass accrual and adipose reduction, mediated downstream by elevated GH and IGF-1. Anecdotal research accounts consistently describe improvements in body composition with prolonged use, though controlled clinical data is limited.

Sleep Quality

Research has investigated sermorelin for its potential role in slow-wave sleep architecture. GH secretion is closely linked to stage 3 sleep, and the largest nocturnal GH pulse typically coincides with early slow-wave sleep. Anecdotal reports describe improved sleep depth and quality with nightly sermorelin protocols.

Anti-Aging Research Context

Sermorelin has been investigated in anti-aging medicine contexts for its potential role in reversing age-associated decline in GH secretion (somatopause). Research has noted that pituitary somatotroph responsiveness is preserved in older adults even when spontaneous GH secretion is reduced, making GHRH analogues potentially effective at restoring the amplitude of pulsatile GH release.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Somatostatin sensitivity: Sermorelin’s effectiveness is partially attenuated by somatostatin, the GH-inhibitory peptide that rises during daytime hours and in response to elevated blood glucose. Research accounts commonly describe timing injection to periods of low somatostatin tone (pre-sleep on an empty stomach) to mitigate this attenuation.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8°C): Preferred for all storage; reported stable for 12 months or more
• Room temperature: Short-term stability acceptable; refrigerator strongly preferred
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light and moisture: Protect from both

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze reconstituted sermorelin — freezing degrades the peptide
• Bacteriostatic water is the preferred diluent for multi-dose vials
• Discard if the solution becomes cloudy or shows particulate matter

See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is the difference between sermorelin and CJC-1295? Both are GHRH analogues, but they differ markedly in half-life. Sermorelin (GHRH 1-29) has a half-life of approximately 10–20 minutes, requiring injection close to the desired GH pulse. CJC-1295 with DAC incorporates drug affinity complex technology that enables albumin binding, extending its half-life to approximately 6–8 days and enabling once or twice-weekly dosing. CJC-1295 produces a sustained elevation of GH, while sermorelin produces discrete pulsatile stimulation more closely mimicking the endogenous GHRH pattern. See the CJC-1295 profile and Ipamorelin vs Sermorelin comparison.

Can sermorelin and Ipamorelin be used together? Yes. This combination is one of the most commonly reported GH axis stacks in research accounts. Sermorelin binds the GHRH receptor; Ipamorelin binds the ghrelin receptor (GHS-R1a). Because the two peptides act on distinct and complementary pathways, their combination produces a synergistic GH pulse greater than either compound alone.

Is sermorelin safer than synthetic growth hormone? Sermorelin stimulates the pituitary gland’s own GH production rather than introducing exogenous GH. The resulting GH release is subject to the body’s normal feedback regulation, including somatostatin inhibition and IGF-1 feedback, which limits the potential for supraphysiological GH exposure. Human research trials of sermorelin have not identified the same safety concerns associated with pharmacological doses of exogenous GH.

Was sermorelin ever FDA-approved? Yes. Sermorelin acetate (Geref, Serono) was FDA-approved for the diagnosis of GH deficiency in children and for treatment of idiopathic GH deficiency. The commercial product was voluntarily withdrawn from the US market in 2008, not due to safety concerns, but because recombinant synthetic GH products had become more commercially dominant. Compounding pharmacies have continued to produce sermorelin as a research compound.

Related Pages

Goals: Muscle Growth · Sleep · Performance

Class: GHRH Analogues

Comparisons: Ipamorelin vs Sermorelin · CJC-1295 vs Sermorelin

References & Further Reading

• Walker RF. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308. PubMed →
• Prakash A, Goa KL. (1999). Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139–157. PubMed →
• Corpas E, et al. (1993). Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men. Journal of Gerontology, 48(4), M128–133. PubMed →